Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Larimar Therapeutics (LRMR) Operating Expenses (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Operating Expenses for 7 consecutive years, with -$15.2 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Operating Expenses fell 203.19% year-over-year to -$15.2 million, compared with a TTM value of $10.4 million through Dec 2019, down 82.9%, and an annual FY2024 reading of $90.9 million, up 117.66% over the prior year.
  • Operating Expenses was -$15.2 million for Q4 2019 at Larimar Therapeutics, down from $8.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $23.2 million in Q4 2015 and bottomed at -$15.2 million in Q4 2019.
  • Average Operating Expenses over 5 years is $12.8 million, with a median of $14.1 million recorded in 2017.
  • The sharpest move saw Operating Expenses surged 194.19% in 2015, then crashed 203.19% in 2019.
  • Year by year, Operating Expenses stood at $23.2 million in 2015, then crashed by 54.94% to $10.5 million in 2016, then rose by 27.52% to $13.4 million in 2017, then grew by 9.98% to $14.7 million in 2018, then plummeted by 203.19% to -$15.2 million in 2019.
  • Business Quant data shows Operating Expenses for LRMR at -$15.2 million in Q4 2019, $8.6 million in Q3 2019, and $3.7 million in Q2 2019.